Treatment of recalcitrant chronic urticaria with nonsedating antihistamines: Is there evidence for updosing?

Journal of Investigational Allergology and Clinical Immunology

Volumn 23, Issue 3, 2013, Pages 141-144

  Sánchez Borges, Mario ^a   Caballero Fonseca, F ^a   Capriles Hulett, A ^a  

^a Centro Medico Docente La Trinidad   (Venezuela)

Author keywords

Antihistamines; Cetirizine; Desloratadine; Fexofenadine; Levocetirizine; Rupatadine; Urticaria

Indexed keywords

ANTIINFLAMMATORY AGENT; BILASTINE; CETIRIZINE; DESLORATADINE; EBASTINE; FEXOFENADINE; HISTAMINE; HISTAMINE H1 RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; IMMUNOMODULATING AGENT; LEVOCETIRIZINE; PLACEBO; RUPATADINE; THROMBOCYTE ACTIVATING FACTOR;

ACQUIRED COLD URTICARIA; BINDING AFFINITY; BURNING SENSATION; CARDIOTOXICITY; CHOLINERGIC SIDE EFFECT; CHOLINERGIC URTICARIA; CHRONIC IDIOPATHIC URTICARIA; CHRONIC URTICARIA; DISEASE CONTROL; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ERYTHEMA; EVIDENCE BASED MEDICINE; HUMAN; NEUROLOGIC DISEASE; PRACTICE GUIDELINE; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECALCITRANT CHRONIC URTICARIA; RECEPTOR OCCUPANCY; RECOMMENDED DRUG DOSE; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION;

CHRONIC DISEASE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; URTICARIA;

EID: 84876818883     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Devillier P, Roche N, Faisy C. Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine: a comparative review. Clin Pharmacokinet. 2008; 47: 217-30.
2. Humphreys F, Hunter JA. The characteristics of urticaria in 390 patients. Br J Dermatol. 1998; 138: 635-8.
3. Zuberbier T, Asero R, Bindslev-Jensen C, Canonica GW, Church MK, Gimenez-Arnau AM, Grattan CE, Kapp A, Maurer M, Merk HF, Rogala B, Saini S, Sanchez-Borges M, Schmid-Grendelmeier P, Schunemann H, Staubach P, Vena GA, Wedi B; Dermatology Section of the European Academy of Allergology and Clinical Immunology; Global Allergy and Asthma European Network, European Dermatology Forum, World Allergy Organization. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy. 2009; 64: 1427-43.
4. Gimenez-Arnau A, Izquierdo I, Maurer M. The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo-controlled treatment with rupatadine 10 and 20 mg. J Eur Acad Dermatol Venereol. 2009; 23: 1088-91.
5. Zuberbier T, Munzberger C, Haustein U, Trippas E, Burtin B, Mariz SD, Henz BM. Double-blind crossover study of high-dose cetirizine in cholinergic urticaria. Dermatology. 1996; 193: 324-7.
6. Kameyoshi Y, Tanaka T, Mihara S, Takahagi S, Niimi N, Hide M. Increasing the dose of cetirizine may lead to better control of chronic idiopathic urticaria: an open study of 21 patients. Br J Dermatol. 2007; 157: 803-4.
7. Asero R. Chronic unremitting urticaria: is the use of antihistamines above the licensed dose effective? A preliminary study of cetirizine at licensed and above-licensed doses. Clin Exp Dermatol. 2007; 32: 34-8.
8. Finn AF, Kaplan AP, Fretwell R, Qu R, Long J. A double-blind, placebocontrolled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol. 1999; 103: 1071-8.
9. Nelson HS, Reynolds R, Mason J. Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2000; 84: 517-22.
10. Siebenhaar F, Degener F, Zuberbier T, Martus P, Maurer M. High-dose desloratadine decreases wheal volume and improves cold provocation tresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. J Allergy Clin Immunol. 2009; 123: 672-9.
11. Staevska M, Popov TA, Kralimarkova T, Lazarova C, Kraeva S, Popova D, Church DS, Dimitrov V, Church MK. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in diffi cult-to-treat urticaria. J Allergy Clin Immunol. 2010; 125; 676-82.
12. Barron S, Ramis I, Garcia-Rafanell J, Merlos M. Inhibitory activity of rupatadine on pro-infl ammatory cytokine production, relationship with binding affi nity. Methods Find Exp Clin Pharmacol. 2005; 27 (Suppl): 161-2 (abstract).
13. Peterson LJ, Church MK, Skov PS. Platelet-activating factor induces histamine release from human mast cells in vivo, which is reduced by local nerve blockade. J Allergy Clin Immunol. 1997; 99: 640-7.
14. Gimenez-Arnau A, Pujol RM, Ianosi S, Kaszuba A, Malbran A, Poop G, Donado E, Perez I, Izquierdo I, Arnaiz E, The Rupatadine Study Group. Rupatadine in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled multicenter study. Allergy. 2007; 62: 539-46.
15. Dubertret L, Zalupca L, Cristoroulo T, Benea V, Medina I, Fantin S, Lahfa M, Perez I, Izquierdo I, Arnaiz E. Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Eur J Dermatol. 2007; 17: 223-8.
16. Metz M, Scholz E, Ferran M, Izquierdo I, Gimenez-Arnau A, Maurer M. Rupatadine and its effects on symptom control, stimulation time, and temperature tresholds in patients with acquired cold urticaria. Ann Allergy Asthma Immunol. 2010; 104: 86-92.
17. Godse KV. Ebastine in chronic spontaneous urticaria in higher doses. Indian J Dermatol. 2011; 56: 597-8.
18. Gillard M, Benedetti MS, Chatelain P, Baltes E. Histamine H1 receptor occupancy and pharmacodynamics of second generation H1-antihistamines. Infl amm Res. 2005 54: 367-9.
19. Simons KJ, Benedetti MS, Simons FE, Gillard M, Baltes E. Relevance of H1-receptor occupancy to H1-antihistamine dosing in children. J Allergy Clin Immunol. 2007 Jun; 119(6):1551-4.